RevitalVision reports positive clinical data for infantile nystagmus treatment

By AI, Created 10:42 AM UTC, May 20, 2026, /AGP/ – RevitalVision says a randomized study published in the British Journal of Ophthalmology found its digital therapeutic improved visual function in patients with infantile nystagmus. The results could widen treatment options for a congenital eye movement disorder that has long had limited non-invasive care.

Why it matters: - Infantile nystagmus has few treatment options, and the condition can reduce visual acuity, depth perception and day-to-day function. - RevitalVision says the study provides the first randomized controlled evidence that its digital therapeutic can improve vision in this patient group. - The findings suggest a non-invasive therapy could help patients with a disorder that often affects lifelong visual performance.

What happened: - RevitalVision announced the publication of positive clinical data for its digital therapeutic in the British Journal of Ophthalmology. - The study, titled “Efficacy of perceptual learning among patients with Infantile Nystagmus,” was conducted at Shamir Medical Center in Israel. - The trial tested a structured visual perceptual learning program designed to improve cortical visual processing. - Patients in the study showed statistically significant gains in visual acuity, contrast sensitivity and functional vision. - Lead researcher Dr. Sigal Zmujack-Yehiam said patient-reported outcomes showed the improvements affected daily functioning, not just clinical test scores.

The details: - Infantile nystagmus is a congenital eye movement disorder present from early infancy and marked by involuntary, rhythmic eye oscillations. - The condition can make steady vision difficult and interfere with activities that depend on clear sight. - Most patients’ vision typically ranges from 20/40 to 20/80 Snellen with best optical correction. - Infantile nystagmus affects about 1 in 1,000 people, or 0.1% of the general population. - RevitalVision is an FDA-cleared perceptual learning software program that uses patient-specific visual stimulation. - The company says the program has been clinically validated in adult amblyopia, keratoconus, post-cataract surgery and presbyopia, among other conditions. - The study found significant improvement in near and distance best-corrected visual acuity. - 46% of treated subjects reached driving-license vision of 20/40. - The study also found significant gains in contrast sensitivity, stereoacuity and binocular vision. - 50% of the 26 patients reported subjective improvements in both distance and near vision. - 42% reported better night vision. - 76.9% said they would recommend the treatment to others. - The full study is available in the British Journal of Ophthalmology: the full study.

Between the lines: - The data add clinical support for a brain-based, software-delivered approach to vision training rather than a purely optical or surgical one. - The reported gains in functional and patient-reported outcomes matter because infantile nystagmus affects how people see in everyday settings, not just on eye exams. - The company is positioning RevitalVision as a broader platform for vision disorders, with nystagmus now joining earlier use cases.

What’s next: - RevitalVision will likely use the publication to support broader adoption of its digital therapeutic among eye care specialists. - The study may also help inform future research on perceptual learning for other vision disorders. - The company says progress is remotely monitored by trained clinicians, which could make the program easier to scale if adoption grows.

The bottom line: - RevitalVision now has randomized trial evidence that its digital therapeutic can improve multiple measures of vision in infantile nystagmus, a condition with limited treatment options.